Koers MustGrow Biologics Corp. Canadian Securities Exchange
Aandelen
MGRO
CA62822A1030
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- CAD | -.--% | +6,74% | -28,57% |
Omzet 2023 * | - | Omzet 2024 * | - | Marktkapitalisatie | 64,33 mln. 47,44 mln. 44,06 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 * | - | Nettowinst (verlies) 2024 * | - | EV/omzet 2023 * | - |
Nettoliquiditeiten 2023 * | - 0 0 | Nettoliquiditeiten 2024 * | - 0 0 | EV/omzet 2024 * | - |
K/w-verhouding 2023 * |
-13,9
x | K/w-verhouding 2024 * |
-
| Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 88,6% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Corey Giasson
CEO | Chief Executive Officer | 46 | 15-03-18 |
Todd Lahti
DFI | Director of Finance/CFO | 58 | 17-12-18 |
Colin Bletsky
COO | Chief Operating Officer | 49 | 15-03-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Brian Quigley
BRD | Director/Board Member | 50 | 17-07-19 |
Brad Munro
CHM | Chairman | 64 | 15-03-18 |
Corey Giasson
CEO | Chief Executive Officer | 46 | 15-03-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,30% | 46,03 mld. | |
+52,73% | 44,55 mld. | |
+7,15% | 40,8 mld. | |
-8,78% | 28,25 mld. | |
+18,68% | 27,71 mld. | |
-21,92% | 18,82 mld. | |
+14,62% | 13,91 mld. | |
+31,85% | 12,43 mld. | |
+4,47% | 10,81 mld. |
- Beurs
- Aandelen
- Aandeel MustGrow Biologics Corp.
- Aandeel MustGrow Biologics Corp. - Canadian Securities Exchange